MarketWatch39m
McKesson Shares Jump After FY25 Outlook Boost, Strong 2Q Sales
Shares of McKesson climbed after the drug distributor raised its fiscal-year guidance and reported strong sales growth during its fiscal second quarter. The stock was up 11%, at $610.99, in midday ...
Stock market today: Wall Street ticks higher ahead of the Fed’s decision on interest rates
U.S. stocks are ticking higher ahead of the Federal Reserve’s announcement coming later in the afternoon about what it will ...
McKesson (MCK) Gets a Buy from Evercore ISI
In a report released today, Elizabeth Anderson CFA from Evercore ISI maintained a Buy rating on McKesson (MCK – Research Report), with a ...
McKesson price target raised to $651 from $642 at TD Cowen
TD Cowen analyst Charles Rhyee raised the firm’s price target on McKesson (MCK) to $651 from $642 and keeps a Buy rating on the shares.
McKesson's Fiscal Q2 EPS Tops Forecast
McKesson's earnings for its fiscal 2025 second quarter exceeded expectations, despite special charges that cut into net ...
These Analysts Boost Their Forecasts On McKesson Following Upbeat Earnings
McKesson (NYSE:MCK) reported better-than-expected second-quarter financial results on Wednesday. McKesson reported quarterly ...
McKesson upgraded at Baird on Core Ventures deal after Q2 beat
Baird upgraded McKesson (NYSE:MCK) to outperform from neutral on Thursday, citing the updates the medical distributor gave ...
What you need to know in Baltimore’s opioid case before it heads to jurors
Fletcher-Hill sends the case to the jury for consideration. Baltimore alleges that the companies, McKesson and AmerisourceBergen, flooded the city with hundreds of millions of addictive pain pills ...
McKesson Corp (MCK) Q2 2025 Earnings Call Highlights: Record Revenue and Strategic Growth ...
McKesson Corp (MCK) reports a 21% revenue increase and raises fiscal 2025 EPS guidance amid strategic expansions and ...